Today, JDRF and Diabetes UK announce their continued commitment to revolutionising the treatment of type 1 diabetes by awarding £490,000 to fund the next generation of immunotherapy research.
The award will allow for more clinical trials, and improve the way they are carried out, through the Type 1 Diabetes UK Immunotherapy Consortium (T1D UK). Set up in 2015 with major funding from the two charities, the network now aims to have a clinical trial centre within 50 miles of 50% of the UK population so that more children and adults can take part in vital research; speeding up the development of new treatments for the condition that currently affects 400,000 people in the UK
A number of immunotherapies have shown promise to treat type 1, but multiple trials are needed before a drug can be licensed. By utilising a network of experts and facilities, the consortium will help to fast-track this process and get immunotherapy drugs to market sooner. Scientists believe these treatments will result in an effective way to slow or prevent type 1 in the future, paving the way towards a cure.
Bigger, smarter, faster research into immunotherapy
Type 1 happens when the immune system destroys insulin-producing cells in the pancreas. In the last 15 years, treatments which act on the immune system have become routine for autoimmune conditions, such as rheumatoid arthritis and psoriasis, but type 1 has been left behind.
The only current treatment available involves replacing the insulin people with type 1 can no longer make themselves, through injections or a pump. The condition has been treated this way ever since the discovery of insulin, nearly a century ago. But insulin is hard to use and as a result less than 30% of people with type 1 manage to achieve blood glucose control that can reduce their risk of developing serious type 1-related complications.
Professor Colin Dayan, at Cardiff University, leads T1D UK’s network of research centres. He explained: “Insulin is too difficult. It’s a blessing we have it because it keeps people with type 1 diabetes alive – people were dying very quickly 100 years ago. But it’s also a curse because it’s so difficult to use – and this is what people with type 1 are facing every day for the rest of their lives.”
With help from JDRF and Diabetes UK, T1D UK is working to change this. So far, the consortium has increased the number of people with type 1 taking part in vital research five-fold, completed three ground-breaking clinical trials and is currently running nine more. The charities are confident this new funding will further accelerate progress and ensure new treatments are delivered quicker.
Professor Dayan, who will expand T1D UK with the new award, said: “We will focus on making immunotherapy research bigger, smarter and faster. We plan to increase the number of clinical trials being run in the UK and make each trial more efficient, so they can be conducted in half the time and with half the number of volunteers. This will enable us to collect the evidence required to get a drug licensed, and made available in the diabetes clinic, sooner than is currently possible.”
Intervening early in type 1 diabetes
Across the UK, approximately 10,000 people every year are diagnosed with type 1 – around half of them children. A licensed immunotherapy could allow doctors to intervene quickly at diagnosis, to treat the underlying cause of their condition and help protect the insulin-producing cells in their pancreas that are still functioning.
Ruby Wain was diagnosed with type 1 in 2017 when she was 23 years old. She took part in one of the consortium’s trials soon after, which was testing a drug that hoped to slow type 1 and preserve a person’s capacity to produce insulin. She said: “My doctor has told me I’m still making some of my own insulin, so my pancreas is still doing some of the work for me. It’s hard to say what would be the case if I hadn’t taken part in the trial, but I’m really glad I did. That extra support right at the start was invaluable for me.”
Rachel Connor, UK Director of Research Partnerships for JDRF, said: “We won’t let new type 1 diabetes treatment insights lie undiscovered within immunotherapy study data. Our funding will empower more scientists to coordinate and integrate data from a greater number of studies. This will accelerate research progress and bring swifter change for people living with the condition.”
Simi Ahmed, JDRF Scientific Program Manager, Research, said: “The Immunotherapy Consortium is positioned to become a role model in the type 1 diabetes community, increasing the amount of people who can take part in research, such that multiple trials may be run concurrently across the globe without competing with each other. Moreover, the model of partnership with both industry and academia uniquely positions the Consortium to influence the design of future studies, allowing for an unprecedented opportunity in the field to combine and compare results from different trials.”
Dr Elizabeth Robertson, Director of Research at Diabetes UK, said: “Our new funding builds upon the excellent work undertaken to date by the Immunotherapy Consortium, enabling UK scientists to take bold steps and make sure the benefits of research reach people with type 1 diabetes as soon as possible.
“Immunotherapies would represent a major shift in the way we combat type 1 diabetes – moving us from treating the symptoms to treating the cause. In the future, this could mean we have ways of halting the immune system’s attack in people newly diagnosed, potentially protecting them against serious complications, and of preventing the immune attack entirely in people at risk – helping to make type 1 diabetes a condition of the past.”